D Edwards, Muse does work, and probably close to 100% in psychogenic ED, and it works in mild to moderate organic ED, and some severe ED and they are working in a combination that will improved this.
The psychogenic patient will refill little, he will gain the confident he needs and keep going on his own. The others are going to refill and even a %20 refill will be a great one, a 10% will assure profits.
The rubbing gels are poor conceptual products and will not take market , the orals will take some market, but even the 3% that will see blue will end up in Muse cause physicians will not prescribed to this group that drug again and suggest Muse as alternative, and many other problems like drug interactions will suit Muse better than the orals.
This is not the problem. The stock will not have gone to $42, because this was wildly known at the time.
The problem is production, If management reassure me full production of both NJ plants for mid 98 I am a holder, if earlier I am a buyer.
But I do not believe them. |
